A Phase 1 Study of Fosbretabulin in Combination With Everolimus in Neuroendocrine Tumors (Grades 1-3) That Have Progressed After at Least One Prior Regimen for Metastatic Disease

This is a single center, open label, phase I study involving grade I-III gastroenteropancreatic neuroendocrine tumors, consisting of a dose escalation Part A followed by an expansion cohort Part B. On Part A Patients will be treated with daily oral everolimus. Fosbretabulin will be administered IV either q3 weekly or q weekly based on PO CRM cohort. Part B: Once the investigators have established an MTD in Part A, the investigators will be treating 15 more patients at that dose combination. The primary and secondary objectives of the expansion cohort will be similar to Part A of the study, i.e., to establish a safety profile of the experimental drug combination and to collect and assess efficacy data. Patients will be treated with concurrent everolimus and fosbretabulin for 12 weeks.

开始日期2017-03-06

申办/合作机构

University of Kentucky

NCT01701349

/ Withdrawn临床3期

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Fosbretabulin Tromethamine (CA4P) in Combination With Paclitaxel and Carboplatin in Anaplastic Thyroid Carcinoma (FACT2)

This is a multicenter, double-blind, placebo-controlled, randomized study of fosbretabulin given with chemotherapy (paclitaxel and carboplatin) compared to placebo given with chemotherapy (paclitaxel and carboplatin) in subjects with anaplastic thyroid cancer (ATC). The primary objective of the study is to determine overall survival. A maximum of 300 subjects will be recruited from approximately 75 multinational sites of which approximately 35 will be located in the United States.

开始日期2015-03-01

申办/合作机构

Oncotelic Therapeutics, Inc.

NCT02279602

/ Completed临床2期

Rollover for Study OX4218s, A P2 Study to Investigate Safety and Activity of Fosbretabulin Tromethamine in the Treatment of Well-Differentiated, Low-to-Intermediate-Grade Unresectable, Recurrent or Metastatic PNET or GI-NET With Elevated Biomarkers

Subjects achieving a clinical response in study OX4218s with a biomarker reduction or symptom response are eligible to enroll in this rollover study to continue once every three weeks fosbretabulin infusions for up to one year.

开始日期2014-12-01

申办/合作机构

Oncotelic Therapeutics, Inc.

100 项与康普瑞丁磷酸二钠相关的临床结果

登录后查看更多信息

100 项与康普瑞丁磷酸二钠相关的转化医学

登录后查看更多信息

100 项与康普瑞丁磷酸二钠相关的专利（医药）

登录后查看更多信息

932

项与康普瑞丁磷酸二钠相关的文献（医药）

2025-05-01·BIOMATERIALS

Pickering emulsion with tumor vascular destruction and microenvironment modulation for transarterial embolization therapy

Article

作者: Feng, Liang-Zhu ; Yu, Chao ; Zhang, Lin-Zhu ; Liu, Zhuang ; Qin, Juan ; Wang, Duo ; Teng, Gao-Jun ; Zhang, Lei ; Yang, Wei-Hao

In the clinic, Lipiodol chemotherapeutic emulsions remain a main choice for patients diagnosed with hepatocellular carcinoma (HCC) via the mini-invasive transarterial chemoembolization (TACE) therapy. However, the poor stability of conventional Lipiodol chemotherapeutic emulsions would result in the fast drug diffusion and incomplete embolization, inducing systemic toxicity and impairing the efficacy of TACE therapy. Therefore, it is of great importance to construct alternative formulations based on commercial Lipiodol to achieve the improved efficacy and safety of HCC treatment. Herein, calcium phosphate (CaP) nanoparticles-stabilized Lipiodol Pickering emulsion (CaP-LPE) with improved stability and pH-responsiveness is prepared and utilized for the encapsulation of combretastatin A4-phosphate (CA4P), a clinically approved vascular disrupting agent. The obtained CA4P-loaded CaP-LPE (CCaP-LPE) was shown to be enhanced stability compared to conventional Lipiodol emulsion and pH-responsive release of the encapsulated drugs. On one hand, the released CA4P could disrupt tumor vascular and cut off the blood supplying of tumor cells, thus starving cancer cells. Moreover, it was revealed that CCaP-LPE could reverse immunosuppressive tumor microenvironment (TME) by neutralizing tumor acidity, leading to the increased infiltration of CD8⁺ T cells and the decreased percentages of immunosuppressive cells. As the result, such CCaP-LPE could effectively shrink orthotopic N1S1 HCC tumors in rats by eliciting a potent antitumor immune response. Therefore, this study highlights a simple strategy to construct a novel LPE with the potencies of tumor vascular disruption and TME modulation, holding a great promise for TAE therapy of HCC.

2025-02-01·INTERNATIONAL JOURNAL OF PHARMACEUTICS

Smart release injectable hydrogel co-loaded with liposomal combretastatin A4 and doxorubicin nanogel for local combinational drug delivery: A preclinical study

Article

作者: Malaekeh-Nikouei, Bizhan ; Jaafari, Mahmoud Reza ; Mahmoudi, Asma ; Mohammadi, Marzieh ; Malek, Saba

Surgical resection and postoperative adjuvant chemotherapy have enhanced the outlook for breast cancer patients. However, tumor relapse and serious side effects of chemotherapy continue to impact patients' quality of life. Designing injectable composite hydrogel made of biodegradable polymers providing sustained release of antiangiogenic and chemotherapeutic agents might play a vital role in elimination of cancer cells. In this regard, we developed dextran based composite hydrogel incorporating doxorubicin-loaded dual-sensitive pH-redox nanogels (DOX-DSNG) and combretastatin A4 (CA4) loaded liposomes which undergo rapid disassembly in cancer cells. CA4 prevents tubulin polymerization and thus inhibits angiogenesis by binding to vascular endothelial tubulin. The results showed that DOX-DSNGs were negatively charged and 144.8 ± 0.85 nm in size. Besides, the size of CA4 loaded liposomes were 102.35 ± 4.22 nm and were negatively charged. Encapsulation efficiency of DOX-DSNGs and CA4 loaded liposomes were 100 % and 89 %, respectively. After loading into the hydrogel structure, doxorubicin and CA4 were gradually released from the composite hydrogel for up to 21 days. DOX-DSNGs and CA4 loaded liposomes showed a dose-dependent cytotoxic effect against 4 T1 breast cancer cells. Thereafter, the anti-neoplastic effect and survival study of the composite hydrogel was evaluated in vivo in tumor-bearing mice. The composite hydrogel significantly reduced tumor volume (from 116 mm³ to 38 mm³) with negligible organ damage, while showed lower cardiotoxicity in 28 days. In conclusion, our results revealed that injectable composite dextran-based hydrogel incorporated with DOX-DSNG and CA4 loaded liposomes could be used as an efficient delivery platform for combination therapies in treatment of solid tumors.

2025-01-01·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

A novel life for antitumor combretastatins: Recent developments of hybrids, prodrugs, combination therapies, and antibody-drug conjugates

Review

作者: Carradori, Simone ; Fantacuzzi, Marialuigia ; De Filippis, Barbara ; Ammazzalorso, Alessandra ; Giampietro, Letizia ; Amoroso, Rosa ; Maccallini, Cristina

Since their discovery from natural sources, the potent cytotoxic effects of combretastatins were widely studied for the application in antitumor therapy. However, major pharmacokinetic issues as low water solubility and chemical instability of the double bond configuration prevented their use in therapy. A lot of efforts have been directed towards the search of novel strategies, allowing a safer use of combretastatins as anticancer agents. This review analyses the recent landscape in combretastatin research, characterized by the identification of hybrids, prodrugs, and novel combination treatments. Interestingly, the potent cytotoxic agent combretastatin A4 (CA4) was recently proposed as payload in the construction of novel antibody-drug conjugates (ADCs), allowing an efficient targeting of the cytotoxic agent to specific tumors.

项与康普瑞丁磷酸二钠相关的新闻（医药）

2025-02-21

·今日头条

晚期实体瘤治疗新突破：中山大学1期研究揭示口服血管破坏剂的潜力

点击蓝字关注我们【导读】 DX1002是一种口服血管破坏剂，在临床前研究中显示出有希望的结果，导致各种动物模型中的肿瘤脉管系统破坏和异种移植肿瘤坏死。 2025年2月18日，中山大学肿瘤防治中心的研究团队在期刊《Cell Reports Medicine》上合作发表了题为“First-in-human phase 1 study of an orally bioavailable vascular-disrupting agent DX1002 in patients with advanced solid tumors”的研究论文。研究结果表明， DX1002在晚期实体瘤患者中表现出良好的安全性和早期抗肿瘤活性，具有独特的肿瘤血管靶向性，且与化疗联合治疗显示出潜在协同效应，值得进一步临床研究。 https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(25)00042-4 01 研究背景在1990年代，血管靶向疗法（VTT）的使用已被确立为一种可行性，VTT有两种主要类型，即血管破坏剂（VDA）和血管生成抑制剂（AIA）。AIAs可以抑制肿瘤血管的形成，而VDAs可以导致现有肿瘤血管的快速和选择性闭合，并导致缺血和广泛出血性坏死。先前的早期临床试验表明，VDA具有可控的安全性和初步的抗肿瘤疗效。VDA包括两个主要类别，即单克隆抗体（如Tarvacin）和小分子VDA。小分子VDA可以根据其分子结构进一步分为秋水仙碱、CA4类似物（如CA4P、ombrabulin、ZD6126、OXi4503、BNC105P、DX1002和C118P）和类黄酮药物（例如DMXAA和MN029）。在动物模型中，这些药物已显示出有希望的抗肿瘤作用。其中一些，包括CA4P、ombrabulin和DMXAA （ASA404），已进入3期试验。然而，其他研究的进展受到阻碍，许多研究仍处于早期临床阶段或已被终止。因此，尽管具有潜力，但尚未有VDA获得抗肿瘤治疗的批准。CA4P是最具代表性的VDA之一，但CA4P的缺陷如分子结构不稳定、靶向作用对肿瘤血管的选择性差，以及对心血管系统和周围神经的毒性等极大地限制了其应用。图形摘要 02 抗肿瘤功效所有17例入组患者均可评估抗肿瘤反应。其中12例患者达到SD，其余5例患者主要对DX1002耐药，总体疾病控制率（DCR）为70.6%。未观察到完全或部分反应；因此，客观缓解率为0%，中位进展时间（TTP）为2.70个月。600mg组中的1例NSCLC患者（患者10）达到SD并持续6.5个月，直到撤回知情同意书并停止治疗。该患者的目标病灶总和仅增加了4.1%。此外，团队选择了1名患者（患者01），其肿瘤病灶适合用对比增强超声（CEUS）观察，并记录了血供的变化。该患者实现了4.5个月的TTP，据观察，随着DX1002给药而出现空腔和坏死，而血液供应显著减少。 CEUS观察到的DX1002药物治疗后，典型肿瘤病灶的血供变化。 03 总结 1. DX1002的安全性和耐受性：在首次人体1期临床试验中，DX1002在50-600mg剂量范围内每日1次给药是安全且耐受性良好的，最大耐受剂量（MTD）为600mg。未观察到剂量限制性毒性（DLT），且与其他血管破坏剂（VDA）相比，DX1002未引起心脏和周围神经毒性，显示出更好的安全性。 2. DX1002的抗肿瘤活性：尽管未观察到完全缓解（CR）或部分缓解（PR），但12例患者达到疾病稳定（SD），总体疾病控制率（DCR）为70.6%。DX1002在临床前研究中显示出破坏肿瘤血管并导致肿瘤组织坏死的能力，但肿瘤周围残留的活细胞可能限制了其作为单一疗法的抗肿瘤活性。 3. DX1002的独特机制： DX1002通过在CA4二苯乙烯结构的双键位置引入羧基，增强了稳定性，并显示出对肿瘤血管的选择性破坏，而不伤害正常血管，表明其具有更好的安全性和靶向性。 4. 联合治疗的潜力：临床前研究表明，DX1002与化疗联合使用可增强抗肿瘤效果。3例患者在DX1002治疗后接受后续治疗（如化疗）表现出部分缓解（PR），提示DX1002可能使肿瘤对化疗重新敏感，支持其在联合治疗中的进一步研究。 5. 未来研究方向：基于1期试验的结果，DX1002的推荐2期剂量（RP2D）为每日1次600mg，连续21天给药。2期临床试验（CTR20200996）已启动，进一步评估DX1002单药及与化疗联合治疗的疗效和安全性。参考资料： 1.Pettit, G.R. ∙ Singh, S.B. ∙ Hamel, E. ... Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4 Experientia. 1989; 45:209-211 2.Pettit, G.R. ∙ Singh, S.B. ∙ Boyd, M.R. ... Antineoplastic Agents. 291. Isolation and Synthesis of Combretastatins A-4, A-5, and A-6 J. Med. Chem. 1995; 38:1666-1672 [Erratum to document cited in CA122:290568] 【关于投稿】转化医学网（360zhyx.com）是转化医学核心门户，旨在推动基础研究、临床诊疗和产业的发展，核心内容涵盖组学、检验、免疫、肿瘤、心血管、糖尿病等。如您有最新的研究内容发表，欢迎联系我们进行免费报道（公众号菜单栏-在线客服联系），我们的理念：内容创造价值，转化铸就未来！转化医学网（360zhyx.com）发布的文章旨在介绍前沿医学研究进展，不能作为治疗方案使用；如需获得健康指导，请至正规医院就诊。热门推荐活动点击免费报名 🕓 全国｜2024年12月-2025年03月 ▶ 中国转化医学产业大会 🕓 上海｜2025年02月28日-03月01日 ▶ 第四届长三角单细胞组学技术应用论坛暨空间组学前沿论坛点击对应文字查看详情

临床3期临床1期临床结果

2024-11-06

·GlobeNewswire-Health Care

ONCOTELIC CLINICAL PRESENTATIONS AT SITC 2024

AGOURA HILLS, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its presentation at SITC 2024. Dr. Cynthia Lee, VP of R&D will be presenting Sapu Bio pipeline of TGFB2 therapeutics. For additional information please go to: https://www.sitcancer.org/home. Dr. Lee has been leading our R&D programs for the past several years including the buildout of our GMP facility in San Diego. The presentations are: Abstract Number 198: TGFB2 mRNA levels prognostically interact with Interferon-alpha receptor activation of IRF9 and IFI27, and makers for tumor-associated macrophages impacting overall survival in PDAC. Authors Sanjive Qazi, Cynthia Lee, Vuong Trieu Abstract Number 218: Evaluating the prognostic impact of Transforming growth factor beta 2 mRNA levels, in conjunction with Interferon-gamma receptor activation of IRF5 and expression of CD276/B7-H3 in low-grade gliomas. Authors Sanjive Qazi, Anthony Maida, Vuong Trieu Abstract Number 1444: Meta-analysis comparing the incidence of serious adverse events, overall survival, and progression-free survival in PDAC patients harboring unresectable tumors treated with mFOLFIRINOX or FOLFIRINOX. Authors Vuong Trieu, Sanjive Qazi, Seymour Fein, Anthony Maida, Tenshang Joh About Oncotelic Oncotelic has rare pediatric designation for Diffuse Intrinsic Pontine Glioma (“DIPG” through OT-101) through its 45% joint venture, GMP Biotechnology Limited, melanoma (through CA4P), and Acute Myeloid Leukemia (through OXi 4503). Oncotelic acquired PointR Data Inc. in November 2019 to build an AI driven biotechnology company. Further, Oncotelic acquired AL-101, during the 4th quarter of 2021, for the intranasal delivery of apomorphine. We intend to develop AL-101 for the treatment of Parkinson Disease, erectile dysfunction, female sexual disorder and hypoactive sexual desire disorder. All these ailments have a very large population suffering from them and there is a need for treatments for each. Oncotelic’s first in class TGFB2 therapeutic to treat pancreatic cancer and glioblastoma is being developed through its JV – Sapu Bio. Oncotelic's Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as "may", "expect", "anticipate" "hope", "vision", "optimism", "design", "exciting", "promising", "will", "conviction", "estimate," "intend," "believe", "quest for a cure of cancer", "innovation-driven", "paradigm-shift", "high scientific merit", "impact potential" and similar expressions are intended to identify forward-looking statements. Forward looking statements contained in this press release include, but are not limited to, statements about future plans related to the operations of the JV, taking the JV into an initial public offering or the success thereof, the progress, timing of clinical development, scope and success of future clinical trials, the reporting of clinical data for the Company’s product candidates and the potential use of the Company's product candidates to treat various cancer indications as well as obtaining required regulatory approval to conduct clinical trials and upon granting of approval by the regulatory agencies, the successful marketing of the products; building and the success of our nanoparticle platform and the related success of launching the platform, the development of the Company’s AI suite including but not limited to AI Chatbots, the public access to the Company’s AI suite, the success of the development of the AI suite or any other AI technologies and whether if any or portion thereof the Company’s AI suite or technologies will be commercialized and launched for sale. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements or may not occur at all. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes, taking the Company or its affiliates through initial public offerings. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the Company's Annual Report on Form 10-K/A filed with the SEC on April 19, 2023 and in the company's other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether because of new information, future events, or otherwise. Contact Information: For Oncotelic Therapeutics, Inc.:Investor Relationsir@oncotelic.com

并购信使RNA

2024-10-28

·GlobeNewswire-Health Care

ONCOTELIC PUBLISHED ITS FOURTH PUBLICATION ON TGFB2 THERAPEUTICS

AGOURA HILLS, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its fourth publication of its TGFB2 series. Clinical data demonstrated that pancreatic cancer patients with high expression levels of either TGFB2, IRF9, or IFI27 showed improvement of median overall survival from 16-20 months to 72 months for patients with low levels of expression for both TGFB2 and either IRF9 or IFI27 validating that knockdown of IRF9 and IFI27 as therapeutic targets for TGFB2 therapeutics. https://www.mdpi.com/3003472 The publications of this series are available at Pubmed as follow: 1) TGFB2 mRNA Levels Prognostically Interact with Interferon-Alpha Receptor Activation of IRF9 and IFI27, and an Immune Checkpoint LGALS9 to Impact Overall Survival in Pancreatic Ductal Adenocarcinoma. Qazi S, Trieu V. Int J Mol Sci. 2024 Oct 18;25(20):11221. doi: 10.3390/ijms252011221. PMID: 39457004 2) Transforming Growth Factor Beta 2 (TGFB2) mRNA Levels, in Conjunction with Interferon-Gamma Receptor Activation of Interferon Regulatory Factor 5 (IRF5) and Expression of CD276/B7-H3, Are Therapeutically Targetable Negative Prognostic Markers in Low-Grade Gliomas. Trieu V, Maida AE, Qazi S. Cancers (Basel). 2024 Mar 19;16(6):1202. doi: 10.3390/cancers16061202. PMID: 38539537 Free PMC article. 3) Transforming Growth Factor Beta 2 (TGFB2) and Interferon Gamma Receptor 2 (IFNGR2) mRNA Levels in the Brainstem Tumor Microenvironment (TME) Significantly Impact Overall Survival in Pediatric DMG Patients. Qazi S, Talebi Z, Trieu V. Biomedicines. 2024 Jan 15;12(1):191. doi: 10.3390/biomedicines12010191. PMID: 38255296 Free PMC article. 4) High Intra-Tumor Transforming Growth Factor Beta 2 Level as a Predictor of Poor Treatment Outcomes in Pediatric Diffuse Intrinsic Pontine Glioma. Uckun FM, Qazi S, Trieu V. Cancers (Basel). 2023 Mar 9;15(6):1676. doi: 10.3390/cancers15061676. PMID: 36980562 Free PMC article. Additional information on our current phase 3 can be found at: https://www.youtube.com/watch?v=5KqdbySDRKE About Oncotelic Oncotelic (f/k/a Mateon Therapeutics, Inc.), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic has rare pediatric designation for Diffuse Intrinsic Pontine Glioma (“DIPG” through OT-101) through its 45% joint venture, GMP Biotechnology Limited, melanoma (through CA4P), and Acute Myeloid Leukemia (through OXi 4503). Oncotelic acquired PointR Data Inc. in November 2019 to build an AI driven biotechnology company. Further, Oncotelic acquired AL-101, during the 4th quarter of 2021, for the intranasal delivery of apomorphine. We intend to develop AL-101 for the treatment of Parkinson Disease, erectile dysfunction, female sexual disorder and hypoactive sexual desire disorder. All these ailments have a very large population suffering from them and there is a need for treatments for each. For more information on AL-101, refer to our Annual Report on Form 10-K/A filed with the SEC on April 19, 2023. Oncotelic's Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as "may", "expect", "anticipate" "hope", "vision", "optimism", "design", "exciting", "promising", "will", "conviction", "estimate," "intend," "believe", "quest for a cure of cancer", "innovation-driven", "paradigm-shift", "high scientific merit", "impact potential" and similar expressions are intended to identify forward-looking statements. Forward looking statements contained in this press release include, but are not limited to, statements about future plans related to the operations of the JV, taking the JV into an initial public offering or the success thereof, the progress, timing of clinical development, scope and success of future clinical trials, the reporting of clinical data for the Company’s product candidates and the potential use of the Company's product candidates to treat various cancer indications as well as obtaining required regulatory approval to conduct clinical trials and upon granting of approval by the regulatory agencies, the successful marketing of the products; building and the success of our nanoparticle platform and the related success of launching the platform, the development of the Company’s AI suite including but not limited to AI Chatbots, the public access to the Company’s AI suite, the success of the development of the AI suite or any other AI technologies and whether if any or portion thereof the Company’s AI suite or technologies will be commercialized and launched for sale. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements or may not occur at all. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes, taking the Company or its affiliates through initial public offerings. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the Company's Annual Report on Form 10-K/A filed with the SEC on April 19, 2023 and in the company's other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether because of new information, future events, or otherwise. Contact Information: For Oncotelic Therapeutics, Inc.:Investor Relationsir@oncotelic.com

并购临床3期

100 项与康普瑞丁磷酸二钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	康普瑞丁磷酸二钠	-	DB12577

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
卵巢癌	临床3期	美国	Oncotelic Therapeutics, Inc.	2016-06-01
卵巢癌	临床3期	比利时	Oncotelic Therapeutics, Inc.	2016-06-01
卵巢癌	临床3期	德国	Oncotelic Therapeutics, Inc.	2016-06-01
甲状腺未分化癌	临床3期	美国	Oncotelic Therapeutics, Inc.	2007-08-01
甲状腺未分化癌	临床3期	以色列	Oncotelic Therapeutics, Inc.	2007-08-01
甲状腺未分化癌	临床3期	意大利	Oncotelic Therapeutics, Inc.	2007-08-01
甲状腺未分化癌	临床3期	俄罗斯	Oncotelic Therapeutics, Inc.	2007-08-01
甲状腺未分化癌	临床3期	英国	Oncotelic Therapeutics, Inc.	2007-08-01
输卵管癌	临床3期	-	Azanta A/S	-
胃神经内分泌肿瘤	临床2期	美国	Oncotelic Therapeutics, Inc.	2014-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02055690 (PAZOFOS, Pubmed \| Obstet Gynecol Surv \| Gynecol Oncol) 人工标引	临床2期	复发性卵巢癌	21	Pazopanib+Fosbretabulin	製鹽繭壓憲膚築蓋壓製(蓋鬱鹹齋鬱遞壓衊顧衊) = 遞顧膚簾廠網獵糧獵窪膚餘築範製網襯鑰窪蓋 (憲遞選窪鏇淵觸淵憲鹽, 4.1 ~ NE)	积极	2020-03-01
				Pazopanib	製鹽繭壓憲膚築蓋壓製(蓋鬱鹹齋鬱遞壓衊顧衊) = 膚鬱膚餘壓鏇鑰觸構鏇膚餘築範製網襯鑰窪蓋 (憲遞選窪鏇淵觸淵憲鹽, 1.0 ~ 8.1)
EUCTR2013-005471-40-GB (ESMO2018)	临床2期	复发性卵巢癌	-	Fosbretabulin 54mg/m2 + Pazopanib 600mg/day	觸廠選築衊築網壓夢鹽(願製壓鬱襯憲顧餘淵蓋) = Four patients who received F+P (2 in P1b and 2 in RP2) developed acute hypertension plus reversible secondary cardiac toxicity. The occurrence of cardiac toxicity resulted in premature discontinuation of the trial. 鏇網繭網構餘鹽顧膚廠 (艱齋築範鏇鑰積醖鏇繭 ) 更多	积极	2018-10-20
				Pazopanib 800mg/day
NCT02279602 (OX4219 \| OX4219s, Corporate Publications) 人工标引	临床2期	神经内分泌肿瘤 \| 胃肠道肿瘤	7	Disodium combretastatin A-4 3-O-Phosphate	鏇網膚鬱夢簾繭願襯蓋(齋廠願遞壓廠鹽壓鏇鏇) = anemia, abdominal pain, fatigue, hypertension, and ALT and AST increases 淵膚廠顧艱憲窪製製網 (襯網顧憲積壓鹹膚觸餘 ) 更多	积极	2017-01-20
NCT00653939 (FALCON, CTgov)	临床2期	鳞状非小细胞肺癌	63	carboplatin+Paclitaxel+Bevacizumab (Arm 1: Chemotherapy+Bevacizumab)	顧鹽餘蓋夢繭鬱夢願窪(簾艱構糧醖餘艱範網醖) = 襯繭繭繭艱衊餘襯構選鹽繭夢齋憲襯製簾鹽憲 (築餘憲膚齋獵積餘憲襯, 醖鑰鹹衊顧築艱築窪製 ~ 遞願蓋醖鬱積艱糧艱願) 更多	-	2015-02-09
				carboplatin+Paclitaxel+Bevacizumab+Fosbretabulin (Arm 2: Active Comparator+Fosbretabulin)	顧鹽餘蓋夢繭鬱夢願窪(簾艱構糧醖餘艱範網醖) = 餘範鏇鬱獵獵鹹製憲築鹽繭夢齋憲襯製簾鹽憲 (築餘憲膚齋獵積餘憲襯, 願夢齋壓夢衊夢夢憲顧 ~ 願網願鑰餘鹹築範願廠) 更多
NCT00507429 (FACT, CTgov)	临床2/3期	甲状腺未分化癌	80	Carboplatin+Paclitaxel+CA4P (Arm 1, Active: CA4P + Carboplatin + Paclitaxel)	獵鹹獵餘壓蓋廠廠窪窪(憲糧窪醖夢齋鬱蓋蓋鹹) = 簾積糧艱構齋製膚積憲選衊餘構願壓艱鹹獵醖 (糧選壓鹽淵鏇製願觸壓, 淵鬱鏇鏇範淵鬱簾窪網 ~ 憲範壓鏇艱鏇艱餘遞廠) 更多	-	2014-06-09
				Carboplatin+Paclitaxel (Arm 2, Comparator: Carboplatin + Paclitaxel)	獵鹹獵餘壓蓋廠廠窪窪(憲糧窪醖夢齋鬱蓋蓋鹹) = 鏇鬱鬱醖夢壓繭齋網顧選衊餘構願壓艱鹹獵醖 (糧選壓鹽淵鏇製願觸壓, 醖構憲鬱網蓋築遞鑰築 ~ 顧鑰鏇鏇餘蓋鹽齋積餘) 更多
NCT00060242 (Pubmed \| Thyroid)	临床2期	甲状腺未分化癌	26	Fosbretabulin 45 mg/m(2)	窪鹽膚築積糧糧憲夢鏇(築艱製製觸壓憲鑰構範) = 衊積淵鹽膚鬱淵構夢鬱選襯顧夢範獵衊製窪顧 (齋繭衊壓觸願鏇淵淵顧 ) 更多	-	2009-03-01
ASCO2005	临床1期	前列腺癌 \| 晚期非小细胞肺癌	20	Combretastatin A4 Phosphate (CA4P)	鹽夢網艱膚遞夢製醖廠(構鏇醖積顧憲簾積餘壓) = 鏇廠蓋淵醖壓簾衊襯獵簾築淵範廠襯夢淵築網 (鏇鹽壓淵築憲繭鏇簾窪 ) 更多	-	2005-06-01
NCT00003698 (Pubmed \| J Clin Oncol)	临床1期	实体瘤	-	Combretastatin A4 phosphate	醖鏇獵顧淵願餘鹽廠憲(鹹觸齋餘鬱襯築壓築鬱) = 艱膚衊齋願遞衊築衊遞繭膚鏇廠糧繭觸壓獵糧 (願廠淵襯憲醖廠鬱獵網 )	-	2003-08-01